Aarti Drugs Limited Reports Audited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016
February 08, 2017 at 09:29 am
Share
Aarti Drugs Limited reported audited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, standalone net sales were INR 2,634.6 million compared with INR 2,529.7 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 309.4 million compared with INR 334.4 million for the same period last year. Profit from ordinary activities before tax was INR 223.4 million compared with INR 223.6 million for the same period last year. Net profit for the period was INR 163.4 million or INR 6.75 basic and diluted per share as compared with net profit for the period of INR 156.1 million or INR 6.86 basic and diluted per share for the same period last year.
For the nine months, standalone net sales were INR 8,191.1 million compared with INR 7,737.8 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 1,038.8 million compared with INR 1,014.5 million for the same period last year. Profit from ordinary activities before tax was INR 774.8 million compared with INR 694.2 million for the same period last year. Net profit for the period was INR 537.8 million or INR 22.21 basic and diluted per share as compared with net profit for the period of INR 491.7 million or INR 20.31 basic and diluted per share for the same period last year.
For the quarter, on consolidated basis, net sales were INR 2,896.6 million compared with INR 2,649.9 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 331.9 million compared with INR 339.3 million for the same period last year. Profit from ordinary activities before tax was INR 240.9 million compared with INR 227.8 million for the same period last year. Net profit for the period was INR 178.5 million or INR 7.38 basic and diluted per share as compared with net profit for the period of INR 170.3 million or INR 7.03 basic and diluted per share for the same period last year.
For the nine months, standalone net sales were INR 8,962.7 million compared with INR 8,209.2 million for the same period last year. Profit from operation before other income, financial cost and exceptional items was INR 1,131 million compared with INR 1,027.6 million for the same period last year. Profit from ordinary activities before tax was INR 852.6 million compared with INR 703.8 million for the same period last year. Net profit for the period was INR 598.6 million or INR 24.73 basic and diluted per share as compared with net profit for the period of INR 501.3 million or INR 20.70 basic and diluted per share for the same period last year.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.